Table 2.
Hazard Ratio of oro-tracheal intubation/death (OTI/death) in all population and according to PaO2/FiO2 at admission.
| Unadjusted and adjusted marginal relative hazards of IOT/deatha | ||||||
|---|---|---|---|---|---|---|
| Unadjusted HR (95% CI) | p-value | Adjusted* HR (95% CI) | p-value | Adjusted** HR (95% CI) | p-value | |
| All patients | ||||||
| No pLMWH | 1.00 | 1.00 | 1.00 | |||
| pLMWH | 0.85 (0.35, 2.07) | 0.727 | 0.89 (0.34, 2.29) | 0.806 | 0.66 (0.28, 1.57) | 0.352 |
| Baseline PaO2/FiO2 ≤ 300 mmHg | ||||||
| No pLMWH | 1.00 | 1.00 | 1.00 | |||
| pLMWH | 1.68 (0.65, 4.39) | 0.287 | 1.49 (0.52, 4.23) | 0.458 | 1.40 (0.51, 3.79) | |
| Baseline PaO2/FiO2 > 300 mmHg | Interaction p-value 0.164 | |||||
| No pLMWH | 1.00 | 1.00 | 1.00 | |||
| pLMWH | 0.33 (0.07, 1.48) | 0.146 | 0.25 (0.02, 3.61) | 0.310 | 0.27 (0.03, 2.18) | |
pLMWH prophylactic dose of low molecular weight heparin.
*Adjusted for time-fixed factors: age, gender, time from symptoms onset, comorbidities (cardiovascular diseases, hypertension, COPD/Asthma, diabetes), PaO2/FiO2 at admission.
**Adjusted for time-fixed and time varying factors: age, gender, time from symptoms onset, comorbidities (cardiovascular diseases, hypertension, COPD/Asthma, diabetes), PaO2/FiO2 at admission, time-varying use of immune-therapy, antiviral and steroids and censoring using IPW.
aInitiation of invasive mechanical ventilation or death.